I think the answer to the question of whether Starpharma should pay one single dollar of consultancy fees to the former CEO in her capacity as advisor to the board is self-evident.
Ann: VivaGel BV US FDA Appeal Outcome, page-18
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.2¢ |
Change
-0.001(1.08%) |
Mkt cap ! $38.39M | |||
| Open | High | Low | Value | Volume |
| 9.2¢ | 9.3¢ | 9.1¢ | $210.6K | 2.290M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 467139 | 9.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.4¢ | 152000 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| SPL (ASX) Chart |